Xcout Intel
BrainEver
BrainEver is a privately held biopharmaceutical company headquartered in Paris, France, focused on developing a pipeline of novel therapies.
Subscribe to see BrainEver’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BrainEver at a glance
BrainEver is a biopharmaceuticals company headquartered in France. Its most recent funding round, Series B, raised $35.6M in July 2025. Xcout tracks 8 named people at BrainEver, including Bernard Gilly (Chairman and CEO).
BrainEver leadership
- Bernard GillyChairman and CEO
- Claire FriedelProject Officer (CPO)
- Alain ProchiantzChief Scientific Officer (CSO)
- Anne BousseauChief Medical Officer (CMO)
- Hubert MechainChief Technological and Manufacturing Officer (CTMO)
- Alexia PerouseDirector, representative of iBionext Growth Fund participations
2 more named people on record for BrainEver, with roles, board committees and tenure — see the full roster →
BrainEver funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $35.6M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
BrainEver competitors
A few of BrainEver's closest competitors — see the full list of competitors and alternatives →
AgeneBio, Inc. is a development-stage CNS biopharmaceutical company located in Baltimore, Maryland, focused on discovering and developing innovative therapeutics to preserve and restore brain function.
FundaMental Pharma is a biopharmaceutical spin-off established from Heidelberg University and headquartered in Heidelberg, Germany. Its research focuses on developing novel therapeutic approaches and treatments for neurological disorders.
Nura Bio Inc. is a privately held biopharmaceutical company headquartered in South San Francisco, California, founded in 2018 to develop novel treatments for neurological diseases.
Prazer Therapeutics is a biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company focuses on developing orally available, brain-penetrating small molecule therapeutics utilizing targeted protein degradation technology for novel drug discovery.
Cyllene Therapeutics is a global leader in non-replicating HSV-1 therapeutics headquartered in Paris, France, with additional presence in New York, USA.
1ST Biotherapeutics is a South Korean biopharmaceutical company focused on discovering and developing treatments for neurodegenerative and other central nervous system diseases. Its work is aimed at patients with disorders such as Alzheimer’s disease and related conditions.
Get BrainEver's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BrainEver in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access